Lucy Teves

TL;DR: It is shown that stroke damage can be prevented in non-human primates in which a PSD-95 inhibitor is administered after stroke onset in clinically relevant situations and establishes that tissue neuroprotection and improved functional outcome after stroke is unequivocally achievable in gyrencephalic non- human primates treated with PSd-95 inhibitors.

TL;DR: Regional suppression of TRPM7 is feasible, well tolerated and inhibits delayed neuronal death in vivo and prevented ischemia-induced deficits in LTP and preserved performance in fear-associated and spatial-navigational memory tasks.

TL;DR: Postsynaptic density-95 inhibitors administrated 3 hours after stroke onset reduced infarct volumes and improved long-term neurobehavioral functions in a wide therapeutic window, raising the possibility that they may have future clinical usefulness.

TL;DR: The findings are consistent with a model involving close interaction between lipid rafts and PSDs and a role for lipid rafting in ischemia‐induced signaling pathways.

TL;DR: The enhanced tyrosine phosphorylation of NR2A or NR2B may contribute to alterations in NMDA receptor function or in signaling pathways in the postischemic brain and may be related to pathogenic events leading to neuronal death.